On May 6, 2025, acalabrutinib (Calquence) in combination with bendamustine and rituximab (Rituxan; BR) received approval in ...

The real-world data showed lower rates of atrial fibrillation and hypertension associated with the second-generation Bruton ...

A significant number of patients taking Bruton tyrosine kinase inhibitors (BTKis) for chronic lymphocytic leukemia (CLL) ...

Currently, Medicare has to wait seven years after a traditional drug gets approved by the U.S. Food and Drug Administration ...

Sangamo Therapeutics, Inc. , a genomic medicine company, today announced that the first quarter earnings call originally scheduled for 4:30p.m. Eastern on Monday, May 12 will be postponed to 6:30p.m.

UPPSALA, SE / ACCESS Newswire / May 13, 2025 / Biovica International (STO:BIOVIC-B)(STO:BIOVIC.B)(FRA:9II) - Biovica, a leader in blood-based cancer monitoring, has entered a reference lab agreement ...

Latest preliminary data show continued promising clinical activity in NHL patients, with two complete responses (CR), three ...

The addition of statin medications to contemporary therapies like ibrutinib could significantly improve survival for patients ...

Calquence (acalabrutinib) plus bendamustine and rituximab reduced risk for disease progression or death by 27% compared with ...

The US Department of Health and Human Services has published its proposed rule on the disclosure of drug prices, just in time for the November mid-term elections.

BeiGene Ltd (ONC) marks a milestone with its first GAAP profitability, driven by a 49% revenue increase and strong market ...